SPHK1 promotes metastasis of thyroid carcinoma through activation of the S1P/S1PR3/Notch signaling pathway

Zhao,Zhijing; Ma,Junfeng; Hu,Baoquan; Zhang,Yi; Wang,Shushu

doi:10.3892/etm.2018.6054

SPHK1 promotes metastasis of thyroid carcinoma through activation of the S1P/S1PR3/Notch signaling pathway

Authors:
- Zhijing Zhao
- Junfeng Ma
- Baoquan Hu
- Yi Zhang
- Shushu Wang
View Affiliations

Affiliations: Thyroid‑Breast Surgery Department, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China, Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing 400038, P.R. China
Published online on: April 12, 2018 https://doi.org/10.3892/etm.2018.6054
Pages: 5007-5016

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid carcinoma is characterized by an aggressive behavior, lack of effective targeted therapies and a high rate of relapse. Sphingosine kinase 1 (SPHK1) has been reported to be a critical regulatory factor in the progression of thyroid carcinoma, but the correlation between SPHK1 and clinical prognosis of patients with thyroid carcinoma has remained to be fully elucidated. The present study aimed to systematically assess the roles of SPHK1 in thyroid carcinoma metastasis and further investigate the possible underlying mechanisms. First, the expression of SPHK1 was detected in tissue samples from 53 thyroid carcinoma patients and in thyroid carcinoma cell lines by reverse transcription‑quantitative polymerase chain reaction analysis. Furthermore, the level of phospho‑(p)‑SPHK1 was immunohistochemically detected in human thyroid carcinoma tissue samples. The activity of SPHK1 was measured with a commercial SPHK1 Activity Assay kit. A sphingosine‑1‑phosphate (S1P) competitive ELISA kit was used to determine the extracellular S1P levels. The metastatic potential was assessed by a Transwell assay. In addition, the association between SPHK1 and clinicopathological features of the patients was analyzed. The results indicated that the expression of SPHK1 in thyroid carcinoma samples was significantly higher than in paired adjacent normal thyroid tissues. High levels of SPHK1 were positively correlated with poor overall survival and progression‑free survival. Downregulation of SPHK1 by lentiviral vector expressing SPHK1 small interfering (si)RNA evidently repressed Notch signaling and reduced the migration and invasion of thyroid carcinoma cells in vitro and in a NOD/SCID mouse model. Furthermore, inhibition of SPHK1 by siRNA or treatment with SPHK1 inhibitor 5C sensitized thyroid carcinoma to cisplatin and doxorubicin. In addition, it was demonstrated that silencing of SPHK1 effectively inhibits processes associated with thyroid carcinoma metastasis through the Notch signaling pathway, and SPHK1 may therefore represent a potential therapeutic target in thyroid carcinoma. In conclusion, the present study indicated that high levels of p‑SPHK1 were positively correlated with high levels of S1P which in turn promoted thyroid carcinoma metastasis via the S1P/S1P receptor 3/Notch signaling pathway, suggesting possible prognostic markers and therapeutic targets.

View Figures

View References

1	Schmidt D and Kuwert T: Hybrid molecular imaging in differentiated thyroid carcinoma. Front Horm Res. 45:37–45. 2016. View Article : Google Scholar : PubMed/NCBI
2	Grewal RK, Ho A and Schöder H: Novel approaches to thyroid cancer treatment and response assessment. Semin Nucl Med. 46:109–118. 2016. View Article : Google Scholar : PubMed/NCBI
3	Nixon IJ: Well-differentiated thyroid cancer-are you overtreating your patients? Endokrynol Pol. 67:60–66. 2016. View Article : Google Scholar : PubMed/NCBI
4	Frampton JE: Lenvatinib: A review in refractory thyroid cancer. Target Oncol. 11:115–122. 2016. View Article : Google Scholar : PubMed/NCBI
5	Williams D: Thyroid growth and cancer. Eur Thyroid J. 4:164–173. 2015. View Article : Google Scholar : PubMed/NCBI
6	Schmid D, Ricci C, Behrens G and Leitzmann MF: Adiposity and risk of thyroid cancer: A systematic review and meta-analysis. Obes Rev. 16:1042–1054. 2015. View Article : Google Scholar : PubMed/NCBI
7	Bae YJ, Schaab M and Kratzsch J: Calcitonin as biomarker for the medullary thyroid carcinoma. Recent Results Cancer Res. 204:117–137. 2015. View Article : Google Scholar : PubMed/NCBI
8	Patmanathan SN, Wang W, Yap LF, Herr DR and Paterson IC: Mechanisms of sphingosine 1-phosphate receptor signalling in cancer. Cell Signal. 34:66–75. 2017. View Article : Google Scholar : PubMed/NCBI
9	Farez MF and Correale J: Sphingosine 1-phosphate signaling in astrocytes: Implications for progressive multiple sclerosis. J Neurol Sci. 361:60–65. 2016. View Article : Google Scholar : PubMed/NCBI
10	Guerrero M, Urbano M and Roberts E: Sphingosine 1-phosphate receptor 1 agonists: A patent review (2013–2015). Expert Opin Ther Pat. 26:455–470. 2016. View Article : Google Scholar : PubMed/NCBI
11	Kwong E, Li Y, Hylemon PB and Zhou H: Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism. Acta Pharm Sin B. 5:151–157. 2015. View Article : Google Scholar : PubMed/NCBI
12	Sanllehí P, Abad JL, Casas J and Delgado A: Inhibitors of sphingosine-1-phosphate metabolism (sphingosine kinases and sphingosine-1-phosphate lyase). Chem Phys Lipids. 197:69–81. 2016. View Article : Google Scholar : PubMed/NCBI
13	Furuya H, Shimizu Y, Tamashiro PM, Iino K, Bielawski J, Chan OTM, Pagano I and Kawamori T: Sphingosine kinase 1 expression enhances colon tumor growth. J Transl Med. 15:1202017. View Article : Google Scholar : PubMed/NCBI
14	Huang LS and Natarajan V: Sphingolipids in pulmonary fibrosis. Adv Biol Regul. 57:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
15	Lu PH, Chen MB, Liu YY, Wu MH, Li WT, Wei MX, Liu CY and Qin SK: Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells. Oncotarget. 8:22800–22810. 2017.PubMed/NCBI
16	Li S, Zhou Y, Zheng X, Wu X, Liang Y, Wang S and Zhang Y: Sphk1 promotes breast epithelial cell proliferation via NF-κB-p65-mediated cyclin D1 expression. Oncotarget. 7:80579–80585. 2016.PubMed/NCBI
17	Fan Z, Jiang H, Wang Z and Qu J: Atorvastatin partially inhibits the epithelial-mesenchymal transition in A549 cells induced by TGF-β1 by attenuating the upregulation of SphK1. Oncol Rep. 36:1016–1022. 2016. View Article : Google Scholar : PubMed/NCBI
18	Liang W, Xie Z, Cui W, Guo Y, Xu L, Wu J and Guan H: Comprehensive gene and microRNA expression profiling reveals a role for miRNAs in the oncogenic roles of SphK1 in papillary thyroid cancer. J Cancer Res Clin Oncol. 143:601–611. 2017. View Article : Google Scholar : PubMed/NCBI
19	Guan H, Liu L, Cai J, Liu J, Ye C, Li M and Li Y: Sphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer. Mol Endocrinol. 25:1858–1866. 2011. View Article : Google Scholar : PubMed/NCBI
20	Murakami M, Ichihara M, Sobue S, Kikuchi R, Ito H, Kimura A, Iwasaki T, Takagi A, Kojima T, Takahashi M, et al: RET signaling-induced SPHK1 gene expression plays a role in both GDNF-induced differentiation and MEN2-type oncogenesis. J Neurochem. 102:1585–1594. 2007. View Article : Google Scholar : PubMed/NCBI
21	Brünnert D, Sztachelska M, Bornkessel F, Treder N, Wolczynski S, Goyal P and Zygmunt M: Lysophosphatidic acid and sphingosine 1-phosphate metabolic pathways and their receptors are differentially regulated during decidualization of human endometrial stromal cells. Mol Hum Reprod. 20:1016–1025. 2014. View Article : Google Scholar : PubMed/NCBI
22	Datta A, Loo SY, Huang B, Wong L, Tan SS, Tan TZ, Lee SC, Thiery JP, Lim YC, Yong WP, et al: SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget. 5:5920–5933. 2014. View Article : Google Scholar : PubMed/NCBI
23	Ribeiro FR, Meireles AM, Rocha AS and Teixeira MR: Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: Characterization of eight cell line models and review of the literature on clinical samples. BMC Cancer. 8:3712008. View Article : Google Scholar : PubMed/NCBI
24	Nakamura T, Matsuyama N, Kirino M, Kasai M, Kiyohara S and Ikenaga T: Distribution, innervation, and cellular organization of taste buds in the sea catfish, plotosus japonicus. Brain Behav Evol. 89:209–218. 2017. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Selvam Panneer S, De Palma RM, Oaks JJ, Oleinik N, Peterson YK, Stahelin RV, Skordalakes E, Ponnusamy S, Garrett-Mayer E, Smith CD and Ogretmen B: Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation. Sci Signal. 8:ra582015. View Article : Google Scholar : PubMed/NCBI
27	Liu H, Ma Y, He HW, Zhao WL and Shao RG: SPHK1 (sphingosine kinase 1) induces epithelial-mesenchymal transition by promoting the autophagy-linked lysosomal degradation of CDH1/E-cadherin in hepatoma cells. Autophagy. 13:900–913. 2017. View Article : Google Scholar : PubMed/NCBI
28	Sukocheva O, Wadham C, Gamble J and Xia P: Sphingosine-1-phosphate receptor 1 transmits estrogens' effects in endothelial cells. Steroids. 104:237–245. 2015. View Article : Google Scholar : PubMed/NCBI
29	Xu Y, Dong B, Huang J, Kong W, Xue W, Zhu Y, Zhang J and Huang Y: Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression. Oncotarget. 7:3233–3244. 2016.PubMed/NCBI
30	Okada T, Ding G, Sonoda H, Kajimoto T, Haga Y, Khosrowbeygi A, Gao S, Miwa N, Jahangeer S and Nakamura S: Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. J Biol Chem. 280:36318–36325. 2005. View Article : Google Scholar : PubMed/NCBI
31	Zhang Z, Yan Z, Yuan Z, Sun Y, He H and Mai C: SPHK1 inhibitor suppresses cell proliferation and invasion associated with the inhibition of NF-κB pathway in hepatocellular carcinoma. Tumour Biol. 36:1503–1509. 2015. View Article : Google Scholar : PubMed/NCBI
32	Tsukamoto S, Huang Y, Kumazoe M, Lesnick C, Yamada S, Ueda N, Suzuki T, Yamashita S, Kim YH, Fujimura Y, et al: Sphingosine kinase-1 protects multiple myeloma from apoptosis driven by cancer-specific inhibition of RTKs. Mol Cancer Ther. 14:2303–2312. 2015. View Article : Google Scholar : PubMed/NCBI
33	Yu H, Duan P, Zhu H and Rao D: miR-613 inhibits bladder cancer proliferation and migration through targeting SphK1. Am J Transl Res. 9:1213–1221. 2017.PubMed/NCBI
34	Zhang S, Deng Z, Yao C, Huang P, Zhang Y, Cao S and Li X: AT7867 inhibits human colorectal cancer cells via AKT-Dependent and AKT-Independent mechanisms. PLoS One. 12:e01695852017. View Article : Google Scholar : PubMed/NCBI
35	Li W, Li J, Wang Y, Zhang K, Li N, Tian Z, Ni B, Wang H and Ruan Z: Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma. Oncotarget. 7:80586–80598. 2016.PubMed/NCBI
36	Zhu P, Liao LY, Zhao TT, Mo XM, Chen GG and Liu ZM: GPER/ERK&;AKT/NF-κB pathway is involved in cadmium-induced proliferation, invasion and migration of GPER-positive thyroid cancer cells. Mol Cell Endocrinol. 442:68–80. 2017. View Article : Google Scholar : PubMed/NCBI